I used "major" as aren't they both the two things you have been waiting for ?
1. You keep harping on about OMOMYC alternatives with equal or greater potency and this update implies these hits should be released this month.
2. OMOMYC results earlier this year were only from a very small trial retesting over a larger pool should also be completed & released later this month.
As for why are they doing OMOMYC again if they don't have commercial access to it ? Well I guess that is still indeterminate as last time they spoke of it there was still uncertainty.
I'd assume they continue with it for two reasons - firstly it highlights the ability of phylomers to deliver a drug that as of yet has been undeliverable and therefore attractive to potential partners irrespective of whether it has anything to do with OMOMYC it's just about delivering the undeliverable. Secondly it's just going early on proving the ability to deliver their own OMOMYC alternative ?
- Forums
- ASX - By Stock
- PYC
- Ann: Shareholder Newsletter
PYC
pyc therapeutics limited
Add to My Watchlist
0.40%
!
$1.27

Ann: Shareholder Newsletter, page-5
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.27 |
Change
0.005(0.40%) |
Mkt cap ! $740.7M |
Open | High | Low | Value | Volume |
$1.27 | $1.29 | $1.27 | $406.0K | 319.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 13987 | $1.27 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.29 | 1380 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 13987 | 1.265 |
1 | 15000 | 1.260 |
1 | 12000 | 1.255 |
1 | 4000 | 1.225 |
1 | 20000 | 1.220 |
Price($) | Vol. | No. |
---|---|---|
1.290 | 25630 | 2 |
1.295 | 24500 | 1 |
1.300 | 59168 | 4 |
1.325 | 9001 | 1 |
1.330 | 20000 | 2 |
Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
Featured News
PYC (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online